CA3110224A1 - 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof - Google Patents

2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof Download PDF

Info

Publication number
CA3110224A1
CA3110224A1 CA3110224A CA3110224A CA3110224A1 CA 3110224 A1 CA3110224 A1 CA 3110224A1 CA 3110224 A CA3110224 A CA 3110224A CA 3110224 A CA3110224 A CA 3110224A CA 3110224 A1 CA3110224 A1 CA 3110224A1
Authority
CA
Canada
Prior art keywords
compound
effective amount
administering
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3110224A
Other languages
English (en)
French (fr)
Inventor
Joel Morris
Donn G. Wishka
Omar Diego LOPEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA3110224A1 publication Critical patent/CA3110224A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3110224A 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof Pending CA3110224A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736246P 2018-09-25 2018-09-25
US62/736,246 2018-09-25
PCT/US2019/052410 WO2020068657A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Publications (1)

Publication Number Publication Date
CA3110224A1 true CA3110224A1 (en) 2020-04-02

Family

ID=68136598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3110224A Pending CA3110224A1 (en) 2018-09-25 2019-09-23 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Country Status (7)

Country Link
US (2) US20220033387A1 (https=)
EP (1) EP3856754A1 (https=)
JP (1) JP7520822B2 (https=)
CN (1) CN112888698A (https=)
AU (1) AU2019349424B2 (https=)
CA (1) CA3110224A1 (https=)
WO (1) WO2020068657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用
EP4138843A4 (en) * 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
CN114644668B (zh) * 2020-12-18 2026-04-14 鲁南制药集团股份有限公司 一种合成地西他滨的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DK0841344T3 (da) * 1996-04-09 2002-12-23 Yamasa Corp 1-(2-Desoxy-2-fluor-4-thio-Beta-D-arabinofuranosyl)cytosiner
ES2565929T3 (es) * 2004-10-25 2016-04-07 Dekk-Tec, Inc. Sales de mostaza de isofosforamida y análogos de las mismas como agentes antitumorales
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5616968B2 (ja) 2009-12-18 2014-10-29 株式会社リブラメディシーナ 置換された１−Ｏ−アシル−２−デオキシ−２−フルオロ−４−チオ−β−Ｄ−アラビノフラノース類の製造方法
AU2013241341B2 (en) 2012-03-28 2016-09-08 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
DK2883866T3 (da) 2012-08-13 2019-05-13 Fujifilm Corp MELLEMPRODUKT TIL SYNTESE AF 1-(2-DEOXY-2-FLUOR-4-THIO-beta-D- ARABINOFURANOSYL)CYTOSIN, MELLEMPRODUKT TIL SYNTESE AF THIONUKLEOSID OG FREMGANGSMÅDER TIL FREMSTILLING AF DISSE MELLEMPRODUKTER
CN103626765B (zh) * 2012-08-27 2016-08-10 广东东阳光药业有限公司 取代的氮杂吲哚化合物及其盐、组合物和用途
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6450356B2 (ja) 2016-02-29 2019-01-09 富士フイルム株式会社 液状医薬製剤
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
JP7520822B2 (ja) * 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Also Published As

Publication number Publication date
EP3856754A1 (en) 2021-08-04
JP2022502378A (ja) 2022-01-11
US20220033387A1 (en) 2022-02-03
AU2019349424B2 (en) 2024-04-04
US11254662B2 (en) 2022-02-22
CN112888698A (zh) 2021-06-01
JP7520822B2 (ja) 2024-07-23
WO2020068657A8 (en) 2021-03-18
AU2019349424A1 (en) 2021-03-18
US20210292310A1 (en) 2021-09-23
WO2020068657A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
KR102917037B1 (ko) Mek 억제제 및 이의 치료 용도
CN109152933B (zh) 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
AU2011335882B2 (en) Treatment of JAK2-mediated conditions
US11254662B2 (en) 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
ES2822773T3 (es) Sales de hidrocloruro de N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
JPH05506854A (ja) 局部活性眼用チアジアゾールスルホンアミドカルボニックアンヒドラーゼ抑制剤
US20110015213A1 (en) Quinazoline derivatives
EA019289B1 (ru) Производные аминопиридина, аминопиримидина и амино-1,3,5-триазина
EA023104B1 (ru) Аналоги эпоксиэйкозатриеновой кислоты и способы их получения и использования
US20250179057A1 (en) Mek immune oncology inhibitors and therapeutic uses thereof
JP2020518649A5 (https=)
JP2010520236A (ja) リソフィリンアナログとその使用法
US6251898B1 (en) Medical use of fluorenone derivatives for treating and preventing brain and spinal injury
CN115073442B (zh) 含双硫键化合物、及其制法和药物组合物与用途
RU2812929C1 (ru) Ингибиторы mek и их терапевтическое применение
CA3014395C (en) Carboxamide derivatives useful as rsk inhibitors
HK40063342A (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
US6667306B1 (en) Platelet ADP receptor inhibitors
HK1236527B (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220211

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240819

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241025

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250529

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106